Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy

NCT02527343 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.

NCT NCT02527343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02527343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy
Lead sponsor
Akcea Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
December 28, 2015
Completion date
November 13, 2019
Enrollment
40 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

familial partial lipodystrophy